Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1402164 | 0.85 | ALDH1A1 (0.61) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL1402179 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL2806310 | 0.79 | GPR84 (0.43) | NPC1AHRTRPA1CA1CA2 | |
| SCHEMBL6655939 | 0.77 | ALDH1A1 (0.45) | ALDH1A1HSD17B10HIF1ACYP1B1CYP2D6 | |
| SCHEMBL20554795 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HSD17B10HIF1ACYP1B1CYP1A2 | |
| SCHEMBL30071614 | 0.74 | AHR (0.61) | NPC1AHRTRPA1CA1CA2 | |
| SCHEMBL1440181 | 0.74 | AHR (0.61) | NPC1AHRTRPA1CA1CA2 | |
| SCHEMBL4496612 | 0.73 | RAD52 (0.50) | ALDH1A1HSD17B10HIF1ACYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL7763064 | 0.73 | AHR (0.58) | NPC1AHRTRPA1CA1CA2 | |
| Bromide SCHEMBL7762976 | 0.73 | AHR (0.58) | NPC1AHRTRPA1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313700-B1 | 10-ARYL-11H-BENZO[B]FLUORENE DERIVATIVES AND ANALOGS AS ESTROGENIC COMPOUNDS | AKZO NOBEL NV (NL) | 2005-11-09 | — | — | EP | disclosed |
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| EP-1043325-B1 | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040059004-A1 | 10-ARYL-11H-BENZO[B]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE | MERCK SHARP & DOHME B.V. (NL) | 2004-03-25 | — | — | US | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-0800519-B1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | N.V. ORGANON (NL) | 2003-07-31 | — | — | US | disclosed |
| EP-1313700-A1 | 10-ARYL-11H-BENZO[B]FLUORENE DERIVATIVES AND ANALOGS AS ESTROGENIC COMPOUNDS | Akzo Nobel N.V. (NL) | 2003-05-28 | — | — | EP | disclosed |
| US-6448405-B1 | COUPLING A 2-HALO-5-NITROBENZOIC ACID AND A 2-METHOXYPHENYL BORONIC ACID; CYCLIZING TO A NITROBENZOCOUMARIN; REDUCING TO THE AMINE; CONVERTING TO A COUMARINO(3,4-F)QUINOLINE; REDUCTION TO A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED | 2002-09-10 | — | — | US | disclosed |
| US-6077699-A | PURIFIED NUCLEOTIDE SEQUENCE OF ORF1 GENE OF STREPTOMYCES PRISTINAESPIRALIS OR ITS COMPLEMENT; FOR RECOMBINANT PRODUCTION OF KNOWN AND NOVEL ANTIBIOTICS | AVENTIS PHARMA S.A. (FR) | 2000-06-20 | — | — | US | disclosed |
| US-6071715-A | NUCLEOTIDE SEQUENCES CODING PROTEINS ASSOCIATED WITH TUMOR SUPPRESSION; FOR DIAGNOSIS AND TREATMENT OF WOUNDS, LEUKEMIA, AND CANCER; ANTICARCINOGENIC AGENTS; WOUND HEALING AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-06-06 | — | — | US | disclosed |
| US-6045792-A | A GENETICALLY ENGINEERED PURIFIED PROTEINS OR POLYPEPTIDES COMPRISING THE AMINO ACID SEQUENCE | INCYTE PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| US-5985285-A | INFECTION WITH THE ORGANISM YERSINIA PESTIS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1999-11-16 | — | — | US | disclosed |
| US-5948619-A | NEW COMPOSITIONS WHICH ARE USEFUL IN THE DIAGNOSIS, PREVENTION AND TREATMENT OF CANCER AND NEURONAL DISORDERS. | INCYTE PHARMACEUTICALS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5925733-A | THEY MAY BE USED FOR DETECTING SPECIFIC ANTIBODY POTENTIALLY PRESENT IN THE SERUM OF INFECTED SUBJECTS. THEY MAY ALSO BE USED FOR DESIGNING OR SCREENING PHARMACEUTICAL COMPOUNDS THAT LIMIT VIRAL REPLICATION BY INHIBITING DNA POLYMERASE ACTIVITY. | UNIVERSITY OF WASHINGTON (US) | 1999-07-20 | — | — | US | disclosed |
| US-5919618-A | ISOLATING GENE CODING FOR PROTEIN WHICH CONTROLS AGING; CREATING GENOMIC DNA LIBRARY, TRANSFORMING INTO DEFECTIVE YEAST CELLS, CULTURING, ISOLATIN COMPLEMENTING MUTANTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | ALDH1A1 3161/4885HSD17B10 343/4885HIF1A 4125/4885 |
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | ESRRA, ESRRB, ESRRG | ALDH1A1 1931/4885HSD17B10 179/4885HIF1A 2750/4885 |
| US-20040059004-A1 | 10-ARYL-11H-BENZO[B]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE | ESRRA, ESR2, ESRRB | ALDH1A1 1045/4885HSD17B10 275/4885HIF1A 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.